Ignite Creation Date:
2025-12-24 @ 11:03 PM
Ignite Modification Date:
2025-12-30 @ 4:20 AM
Study NCT ID:
NCT06975969
Status:
RECRUITING
Last Update Posted:
2025-09-10
First Post:
2025-04-23
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Single Center Post-Market Study of Thrombolytic Therapy Using the Versus™ Catheter
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D013927', 'term': 'Thrombosis'}, {'id': 'D014652', 'term': 'Vascular Diseases'}, {'id': 'D016769', 'term': 'Embolism and Thrombosis'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}, {'id': 'D008171', 'term': 'Lung Diseases'}], 'ancestors': [{'id': 'D012140', 'term': 'Respiratory Tract Diseases'}]}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'PROSPECTIVE', 'observationalModel': 'CASE_ONLY'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 10}, 'patientRegistry': False}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2025-09-05', 'type': 'ESTIMATED'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-09', 'completionDateStruct': {'date': '2025-12-31', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-09-03', 'studyFirstSubmitDate': '2025-04-23', 'studyFirstSubmitQcDate': '2025-05-08', 'lastUpdatePostDateStruct': {'date': '2025-09-10', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2025-05-16', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-12-31', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Blood Clot resolution', 'timeFrame': 'Within one week of hospital admission', 'description': 'Number of patients achieving hemodynamic homeostasis as evidenced by pulmonary artery pressure indicating resolution of a pulmonary blood clot'}, {'measure': 'Physician user experience', 'timeFrame': 'Periprocedural', 'description': 'Number of physicians who rate use of the Versus Catheter as "Good \\& Acceptable" or "Very good \\& Acceptable" on a four-point scale'}]}, 'oversightModule': {'isUsExport': False, 'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': True}, 'conditionsModule': {'keywords': ['thrombolysis', 'pulmonary catheter', 'hemodynamic monitoring', 'catheter directed therapy'], 'conditions': ['Blood Clots', 'Vascular Disease', 'Embolism Thrombosis', 'Cardiovascular Diseases', 'Lung Diseases']}, 'descriptionModule': {'briefSummary': 'Assess the functionality of the Versus Catheter for catheter-directed thrombolysis of pulmonary blood clots, including advanced imaging assessment. An evaluation of patient outcomes from the cases included in this study will also be conducted.', 'detailedDescription': 'The objective of this study is to assess the functionality of the Versus™ Catheter for the controlled and selective infusion of physician-specified fluids, including thrombolytics, into the pulmonary artery vasculature in adult patients, including advanced Computerized Tomography Angiogram (CTA) imaging assessment. This study will include an evaluation of patient outcomes and physician user experience with the Versus™ Catheter among up to 10 patients meeting the criteria for enrollment.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '80 Years', 'minimumAge': '18 Years', 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': 'Patients age 18 - 80 years old who present with symptoms requiring intervention with delivery of physician-specified thrombolytics to the pulmonary vasculature, including patients who present with submassive pulmonary embolism (PE), who receive treatment using the Versus™ Catheter.', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Patients 18 - 80 years, inclusive\n* Patients who present with submassive pulmonary embolism (PE)\n* Patients requiring thrombolytic intervention to the pulmonary vasculature\n* Physician decision to use the Versus™ Catheter during the treatment of the patient\n\nExclusion Criteria:\n\n* Concurrent treatment with thrombectomy\n* Concurrent treatment with a catheter-directed thrombolysis device that is NOT the Versus™ Catheter\n* Massive pulmonary embolism (PE)\n* Active bleeding disorder1\n* Recent cerebrovascular accident or transient ischemic attack1\n* Recent neurosurgery1\n* Recent intracranial trauma1\n* Absolute contraindication to anticoagulation1\n* BMI \\> 45kg/m2\n* In the opinion of the investigator, the participant is not a suitable candidate for the study'}, 'identificationModule': {'nctId': 'NCT06975969', 'briefTitle': 'Single Center Post-Market Study of Thrombolytic Therapy Using the Versus™ Catheter', 'organization': {'class': 'INDUSTRY', 'fullName': 'Liquet Medical Inc.'}, 'officialTitle': 'Single Center Post-Market Study of Thrombolytic Therapy Using the Versus™ Catheter', 'orgStudyIdInfo': {'id': 'CP-1001'}, 'secondaryIdInfos': [{'id': '1402 Liquet-UVA-VCU', 'type': 'OTHER_GRANT', 'domain': 'VBHRC Catalyst'}]}, 'armsInterventionsModule': {'armGroups': [{'label': 'Patients who receive treatment using the Versus Catheter', 'description': 'Patients age 18 - 80 years old who present with symptoms requiring intervention with delivery of physician-specified thrombolytics to the pulmonary vasculature, including patients who present with submassive pulmonary embolism (PE), who receive treatment using the Versus™ Catheter.', 'interventionNames': ['Device: Versus™ Endovascular Pulmonary Artery Drug Delivery Catheter']}], 'interventions': [{'name': 'Versus™ Endovascular Pulmonary Artery Drug Delivery Catheter', 'type': 'DEVICE', 'description': "The Versus Pulmonary Artery Catheter is a dual-tip, infusion catheter. Two lumens access and deliver physician-specified fluids, including thrombolytics, into the pulmonary arteries of each lung via a single access site. The Secondary Catheter tip telescopes independently to facilitate infusion into the contralateral lung. The device may allow for assessment of a patient's hemodynamic condition through direct intracardiac and pulmonary artery pressure monitoring. Pressure is measured through an interface between the catheter's fluid lumen and an externally located, FDA-cleared, pressure transducer. The device may include an additional lumen that is in communication with a distal flow-directed balloon.", 'armGroupLabels': ['Patients who receive treatment using the Versus Catheter']}]}, 'contactsLocationsModule': {'locations': [{'zip': '22903', 'city': 'Charlottesville', 'state': 'Virginia', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Nadine Haubrich', 'role': 'CONTACT', 'email': 'cjj4ns@uvahealth.org', 'phone': '434-243-9846'}], 'facility': 'University of Virginia Medical Center', 'geoPoint': {'lat': 38.02931, 'lon': -78.47668}}], 'centralContacts': [{'name': 'Derek Hall, MS', 'role': 'CONTACT', 'email': 'd.hall@liquetmedical.com', 'phone': '301-337-8159'}, {'name': 'Carrie Kuehn, MA, MPH, LPD, RAC-US', 'role': 'CONTACT', 'email': 'c.kuehn@liquetmedical.com', 'phone': '301-337-8159'}], 'overallOfficials': [{'name': 'Luke Wilkins, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'University of Virgina (UVA)'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Liquet Medical Inc.', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}